General Information of Drug (ID: DMOU173)

Drug Name
CP-945598 Drug Info
Synonyms
Otenabant; Otenabant hydrochloride; CP 945598; Otenabant hydrochloride (USAN); CP-945,598; Otenabant (USAN/INN); 1-(8-(2-Chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide monohydrochloride; 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-ethylamino-piperidine-4-carboxamide
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Discontinued in Phase 3 [1]
Cross-matching ID
PubChem CID
10052040
CAS Number
CAS 686344-29-6
TTD Drug ID
DMOU173

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [3]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [4]
Orlistat DMRJSP8 Obesity 5B81 Approved [5]
SR141716A DMCO5JZ Obesity 5B81 Approved [6]
Tebipenem DMVSX6O Urinary tract infection GC08 Phase 3 [1]
Conatumumab DM2UOSN Colorectal cancer 2B91.Z Phase 2 [7]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [8]
SR-147778 DMNAECP Obesity 5B81 Phase 2 [9]
Nimacimab DM21Z68 Diabetic nephropathy GB61.Z Phase 2 [10]
AEF0117 DMQ1GH4 Marijuana use disorder 6C41 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Antagonist [2]

References

1 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
2 Pfizer. Product Development Pipeline. March 31 2009.
3 Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
4 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
5 Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
6 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
7 Clinical pipeline report, company report or official report of AstraZeneca (2009).
8 Company report (Gwpharm)
9 Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
10 Clinical pipeline report, company report or official report of Bird Rock Bio.
11 Clinical pipeline report, company report or official report of Affimed Therapeutics.